Dabogratinib, formerly known by its development code TYRA-300, is an investigational, orally administered small-molecule tyrosine kinase inhibitor that selectively targets fibroblast growth factor receptor 3 (FGFR3).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.